Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis

Area of Science:

• Biochemistry
• Molecular Biology
• Genetics

Background:

• Src homology 2 (SH2)-containing protein tyrosine phosphatase 2 (SHP2) is a key regulator of cellular signaling pathways.
• SHP2, encoded by the PTPN11 gene, possesses distinct structural domains (N-SH2, C-SH2, catalytic PTP domain, C-terminal tail).
• It influences cellular processes via both PTP catalytic activity-dependent and -independent mechanisms.

Purpose of the Study:

• To provide an overview of SHP2 structure and function.
• To discuss the molecular and pathogenic mechanisms of SHP2 in human diseases, focusing on tumorigenesis.
• To explore SHP2 as a potential drug target for cancer therapy.

Main Methods:

• Literature review and synthesis of existing knowledge on SHP2.
• Analysis of the role of PTPN11 mutations in human disorders.
• Discussion of SHP2's involvement in signaling pathways relevant to cancer.

Main Results:

• SHP2 mutations and aberrant expression disrupt signaling pathways, contributing to Noonan syndrome, LEOPARD syndrome, hematological malignancies, and solid tumors.
• SHP2 plays a critical role in the pathogenesis of various human diseases, particularly in cancer development.
• SHP2's involvement in tumorigenesis highlights its significance in cancer biology.

Conclusions:

• SHP2 is implicated in the molecular mechanisms underlying several human diseases, including various cancers.
• Targeting SHP2 presents a promising strategy for cancer prevention and treatment.
• Further research and development of SHP2-specific inhibitors are crucial for therapeutic advancement.